企業概要
Citius Oncology, Inc. is an enterprise dedicated to the development and commercialization of innovative targeted therapies for oncology, with a specific focus on advancing LYMPHIR as an orphan drug for treating adult patients with relapsed or refractory cutaneous T-cell lymphoma. This company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche pharmaceutical solutions rather than mass-market commodities. The organization maintains a market capitalization of $58.26M and reported annual revenue of $3.94M over the trailing twelve months, while the specific employee count is not disclosed in available public records. These valuation and revenue figures indicate that the entity is a small-cap biotechnology firm with a specialized product pipeline, suggesting a business model reliant on high-risk, high-reward research and development initiatives rather than established large-scale manufacturing operations.
財務健全性
The company reported revenue of $3.94M for the trailing twelve months, yet it simultaneously recorded a net income loss of $23,636,232 and an unavailable EBITDA figure, highlighting a significant structural gap where operating expenses substantially exceed top-line generation. This disparity between revenue and net income reveals a heavy cost structure typical of early-stage drug development, where research, clinical trial costs, and administrative overheads are not offset by sales proceeds. Free cash flow stands at -$24,720,178, indicating that the company is burning cash at a rapid pace, which limits its current financial flexibility and necessitates capital raising or reliance on existing reserves to sustain operations. Despite the negative cash flow, the balance sheet holds $7.30M in cash against $3.80M in total debt, resulting in a debt-to-equity ratio of 6.51 that suggests a highly leveraged position relative to shareholder equity. The current ratio of 0.83 indicates that the company's current assets are insufficient to cover its current liabilities, signaling potential short-term liquidity constraints. Furthermore, the Return on Equity is -47.4% and the Return on Assets is -14.0%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or deployed in assets.
バリュエーション評価
Trailing P/E and forward P/E ratios are both unavailable (N/A) due to the company's lack of consistent profitability, meaning traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory. However, the price-to-book ratio is recorded at 0.96, indicating that the market values the company's equity slightly below its book value, which can occur in distressed or loss-making biotech firms. The price-to-sales ratio stands at 14.77, a metric that suggests the market is pricing in significant future growth potential despite current losses, while EV/EBITDA remains unavailable given the negative earnings structure. Regarding trading range, the 52-week high is $6.19 and the 52-week low is $0.49, placing the current share price at a specific point within this wide volatility band relative to recent market highs and lows. Additionally, the stock exhibits a beta of 3.43, which signifies that the share price is highly volatile and tends to move with significantly greater amplitude than the broader market index.
Growth & Income
Revenue growth and earnings growth rates are both unavailable (N/A) in the trailing twelve months, preventing a direct comparison to determine if earnings are growing faster or slower than revenue in the recent period. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, indicating that any generated earnings, if any, are theoretically reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is characteristic of biotechnology companies that prioritize funding clinical trials and regulatory approvals over immediate shareholder returns. The overall growth and income profile for Citius Oncology, Inc. is defined by a reliance on future product approvals and commercialization milestones to drive value, rather than current cash flow generation or dividend distributions.